+3K
Employees
Faced with rising demand for a critical active pharmaceutical ingredient (API), a mid-sized pharmaceutical company needed to rapidly increase production capacity at its Italian facility. EFESO led a debottlenecking initiative, unlocking €2.6M in real benefit and positioning the plant to support future growth.
Industry: Life Sciences
Service: Manufacturing
Service: Operational Excellence
Service: Operations Strategy and Transformation
A mid-sized pharmaceutical company specializing in the production of active pharmaceutical ingredients (APIs). The organization operates production with one of its most strategic APIs manufactured in Italy.
+3K
Employees
+€700M
Annual turnover
15
Countries with production plants
Growing market demand for one of the company’s strategic APIs required a significant capacity increase at its Italian facility. However, the plant faced multiple obstacles:
The company needed to determine the most efficient technological and organizational solution to increase producible volumes while maintaining compliance and optimizing capital and operational expenditures.
A structured debottlenecking initiative enabled the business to identify and prioritize the optimal scenario for implementation, achieving measurable financial and operational improvements beyond expectations.
+€2.6m
Real benefit delivered (vs. €2.49M expected)
-5% to -30%
COGS reduction
+10% to +20%
Yield improvement
EFESO led a multifunctional client team to identify and quantify all production constraints across technology, quality and GMP compliance, waste management and logistics. Each constraint was mapped, analyzed and translated into actionable improvement opportunities.
The approach included:
This methodology ensured both strategic rigor and speed, enabling the organization to act decisively and achieve gains exceeding expectations.